Dechra Veterinary Products

What Dechra Veterinary Products does

Dechra Veterinary Products LLC is the US operating subsidiary of Dechra Pharmaceuticals PLC, a publicly traded UK-based veterinary pharmaceutical group. The US entity, headquartered in Overland Park, Kansas, develops, markets, and distributes a comprehensive portfolio of prescription and non-prescription veterinary pharmaceuticals exclusively to licensed veterinary professionals for companion animals (dogs and cats) and equine patients. The product range spans nine management areas: anesthesia and analgesia, dental, dermatology, endocrinology, fluid therapy, ophthalmics, pain management, supplements and treats, and weight management. Notable proprietary formulations include Mirataz (the first and only FDA-approved transdermal medication for feline weight loss), Solovecin (a long-acting injectable cefovecin antibiotic providing 14 days of therapy in a single dose), Vetoryl (trilostane for canine Cushing's), Felimazole (feline hyperthyroidism), and the VETRADENT dental line featuring proprietary Biotrate technology and VOHC-accepted dental wipes.

The company sells exclusively through the veterinary channel using a combination of direct field sales representatives, veterinary distributors and wholesalers, and the Vetcove e-commerce marketplace. Pricing is quote-based through veterinary distribution rather than publicly disclosed, with the Dechra Rewards semiannual loyalty program offering rebates up to 15% on products purchased through Vetcove to drive repeat purchasing. The company supports veterinary professionals through Dechra Academy, a RACE-approved continuing education platform developed in collaboration with key opinion leaders, and partners with organizations like Not One More Vet, Inc. to address veterinary professional wellbeing.

As a wholly-owned subsidiary of Dechra Pharmaceuticals PLC (listed on the London Stock Exchange), Dechra Veterinary Products benefits from global R&D, manufacturing scale, and a broader portfolio of 50+ country websites spanning North America, Europe, South America, and Asia Pacific. The US subsidiary itself is relatively small (11-50 employees), with operations focused on sales, marketing, and customer service rather than manufacturing. Recent strategic activity includes the November 2025 US launch of Solovecin, the February 2026 VOHC Seal of Acceptance for VETRADENT Dental Wipes, and the November 2025 Human-Animal Bond Certified Company designation, indicating active portfolio expansion and brand-building investment in the US market.

Name

Dechra Veterinary Products

Legal name

Dechra Veterinary Products LLC

Website

https://dechra-us.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Dechra Veterinary Products is the US subsidiary of UK-listed Dechra Pharmaceuticals PLC that develops and sells prescription and non-prescription veterinary pharmaceuticals exclusively to veterinary professionals across nine therapeutic areas for companion animals (dogs and cats) and horses.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)

akta.pro secondary industries

Dermatology & Allergy Drugs (HLAMAEAH), Animal Health OTC Retail (Parasite Control, Basic Care) (HLAMAIAJ), Skin & Coat Supplements (HLAMALAB), Specialty & Condition-Specific Nutraceuticals (e.g., Liver, Eye, Endocrine) (HLAMALAO)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Companion animal therapeutics
• Equine veterinary medicines
• Veterinary dermatology products

Headquarters

HQ city

Overland Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Veterinary Pharmaceuticals: Prescription-only veterinary pharmaceutical products sold to veterinarians, including antibiotics, anti-inflammatories, anesthetics, endocrine drugs, and other therapeutic medications for companion animals (dogs, cats) and equine.
2. Non-Prescription Veterinary Products: Over-the-counter veterinary products including dental care (VETRADENT®), dermatology (shampoos, sprays), supplements, ophthalmic products, and ear cleaners sold through veterinarians.
3. Nutraceuticals and Supplements: Nutritional supplements including fatty acids (EicosaCaps®, Eicosa3FF®, EicosaDerm®), joint supplements (Phycox®), and skin health products (Redonyl® Ultra) sold through veterinary channels.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Dechra Veterinary Products develops, manufactures, and sells prescription and non-prescription veterinary pharmaceuticals and related products for companion animals (dogs and cats) and equine (horses), distributed exclusively through licensed veterinarians and veterinary clinics. The portfolio covers nine therapeutic management areas: Anesthesia and Analgesia, Dental, Dermatology, Endocrinology, Fluid Therapy, Ophthalmics, Pain Management, Supplements and Treats, and Weight Management. Products include branded FDA-approved prescription medications (Zenalpha, Vetoryl, Felimazole, Mirataz, Osurnia, Solovecin, Zycosan) and non-prescription products (VETRADENT dental line, dermatology shampoos/cleansers, nutraceuticals).

Product overview

Dechra Veterinary Products is an international veterinary pharmaceuticals and related products business serving veterinarians exclusively. The company offers an extensive portfolio of prescription and non-prescription veterinary products across multiple animal categories (companion animals including dogs and cats, and horses) and therapeutic areas. The product range includes: anesthetics and sedatives (Zenalpha, Dexmedesed, Tzed, Ketamine), analgesics and anti-inflammatories (Carprovet, Meloxivet), antibiotics and anti-infectives (Solovecin, Clavacillin, Enroquin, Marboquin, Cefpoderm), dermatology products (Malaseb, MiconaHex+Triz, TrizCHLOR, DermAllay, DermaBenSs, MalAcetic, Mal-A-Ket), dental products (VETRADENT line with VOHC acceptance, DenTees), ophthalmic products (OphtHAvet, Puralube), nutritional supplements and fatty acids (EicosaDerm, EicosaCaps, Eicosa3FF), joint health products (Phycox, Vetoryl), endocrine medications (Felimazole, Zycortal), behavior and wellness products (Mirataz), injectable fluids (Vetivex), equine products (Equidone, Zycosan, Orthokine, Osphos), and ear care products (TrizEDTA, EpiKlean, KlearOtic). The company also offers educational resources through Dechra Academy.

Differentiator

Problem solved

Functional benefit

Brands

• VETRADENT: Dental care products for dogs including toothpaste, dental wipes, dental spray, water additives, and veggie chews
• Zenalpha
• Laverdia-CA1
• Zycosan
• Vetivex
• Equidone
• Solovecin
• DermaBenSs/DermAllay/DermaLyte
• Carprovet
• Vetoryl
• Mirataz
• Dechra Academy
• Dechra Rewards
• Eicosa3FF/EicosaCaps
• Mal-A-Ket/MalAcetic
• MiconaHex+Triz
• Phycox
• Redonyl Ultra
• Enroquin
• Marboquin
• Dexmedesed
• Meloxivet
• Emeprev
• Felimazole
• Zycortal
• Tzed
• Osurnia

Products and services

• Zenalpha (medetomidine and vatinoxan hydrochlorides injection) Sedative and analgesic injection for dogs used for restraint during clinical examinations and procedures, and as a preanesthetic to general anesthesia. Licensed veterinarians only.
• Laverdia-CA1 (verdinexor tablets) Oral antiviral tablets for the treatment of lymphoma in dogs. Licensed veterinarians only.
• Zycosan (pentosan polysulfate sodium injection) Injectable polysulfated glycosaminoglycan for the treatment of osteoarthritis in horses. Licensed veterinarians only.
• Vetivex Veterinary Fluids Line of veterinary fluid products including Lactated Ringer's Injection, 0.9% Sodium Chloride Injection, Hypertonic Saline Solution, pHyLyte Injection, and Hartmann's Solution for fluid and electrolyte replenishment in companion animals.
• Equidone Gel (domperidone) Oral domperidone gel for prevention of fescue toxicosis in periparturient mares; the only FDA vet-labeled product for this equine indication.
• Mirataz (mirtazapine transdermal ointment) The first and only FDA-approved transdermal medication for the management of weight loss in cats. Applied topically to the inner ear pinna.
• Solovecin (cefovecin sodium) Long-acting injectable cephalosporin antibiotic for treating common bacterial skin infections in dogs and cats, providing up to 14 days of antimicrobial therapy in a single subcutaneous injection.
• Vetoryl (trilostane) Capsules Oral trilostane capsules for treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's disease) in dogs, available in 5mg, 10mg, 20mg, 30mg, 60mg, and 120mg strengths.
• Felimazole (methimazole coated tablets) Coated methimazole tablets for the treatment of hyperthyroidism in cats, available in 2.5mg and 5mg doses.
• Carprovet (carprofen) Tablets and Chewable Tablets NSAID in flavored tablets and chewable tablets for dogs for relief of pain and inflammation associated with osteoarthritis and postoperative pain.
• Osurnia (florfenicol, terbinafine, betamethasone acetate otic gel) Long-acting otic gel for dogs for treatment of otitis externa associated with susceptible bacteria and yeast.
• Zycortal (desoxycorticosterone pivalate injectable suspension) Subcutaneous injection for replacement therapy of mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison's disease).
• Tzed (tiletamine and zolazepam for injection) Injectable dissociative anesthetic combination for dogs and cats for restraint, minor procedures, and induction of anesthesia.
• Dexmedesed (dexmedetomidine hydrochloride injectable solution) Sterile injectable sedative and analgesic for dogs and cats used for clinical procedures and as a preanesthetic to general anesthesia.
• Meloxivet (meloxicam) Solution for Injection NSAID injection for dogs and cats for control of pain and inflammation associated with osteoarthritis and postoperative pain.
• Osphos (clodronate injection) Bisphosphonate injection for horses for treatment of navicular disease and other orthopedic conditions.
• VETRADENT Dental Care Line Line of pet oral care products for dogs including toothpaste, dental wipes (carrying VOHC Seal of Acceptance for tartar control), dental spray, water additive, powder water additive, and Biotrate veggie dental chews formulated to reduce plaque and tartar with VETRADENT Biotrate Technology.
• Phycox Joint Health Supplements Patented joint health supplement for dogs containing Phycox (a natural source of phycocyanin), glucosamine, MSM, creatine monohydrate, and antioxidants, available in granules, soft chews, and small bites.
• Redonyl Ultra Soft Chews Hypoallergenic nutraceutical soft chews containing Ultra-micronized Palmitoylethanolamide (PEA-um) to support skin health in dogs; trademark licensed from Innovet Italia S.r.l.
• DermaBenSs / DermAllay / DermaLyte Shampoos Dermatology shampoo and conditioner line for dogs and cats including DermaBenSs (soap-free antibacterial/keratolytic), DermAllay (oatmeal-based anti-pruritic), and DermaLyte (hypoallergenic with ceramide complex).
• MalAcetic and MalAcetic ULTRA Ear Cleansers Ear cleansers for dogs and cats with antifungal, antibacterial, and degreasing properties. MalAcetic contains acetic acid and boric acid; MalAcetic ULTRA adds ketoconazole and Tris-EDTA.
• TrizEDTA Aqueous Flush Multi-use aqueous flush containing USP tris-EDTA for cleansing and otic pre-treatment in dogs and cats.
• Dechra Academy On-demand eLearning platform for veterinary professionals offering RACE-approved continuing education courses covering endocrinology, dermatology, oncology, and mental wellness topics in collaboration with key opinion leaders.

Quantifiable outcome

• VETRADENT® Dental Wipes received VOHC Seal of Acceptance for proven tartar control performance
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Not One More Vet, Inc. (NOMV)coreStrategic or Co-development Partner · 3 October 2023Dechra partnered with Not One More Vet, Inc. to develop the Dechra Academy course 'Flavors of Fatigue,' addressing mental health issues in veterinary medicine. The RACE-approved course, taught by Dr. Taylor Miller, covers moral distress, decision fatigue, mental fatigue, sleep deprivation, and compassion fatigue. This partnership demonstrates Dechra's commitment to supporting veterinary professional wellbeing beyond pharmaceutical products.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Boehringer Ingelheim Animal Health: Major global animal health division offering vaccines, pharmaceuticals, and parasiticides across companion animals, livestock, and poultry. Comparable as a broad-line veterinary pharma competitor with presence in dermatology, cardiology, and infectious disease, though much larger and broader than Dechra's specialty focus.
• Zoetis: The largest pure-play animal health company globally, offering a comprehensive portfolio of pharmaceuticals, vaccines, diagnostics, and medicated feed additives across companion and livestock animals. Directly comparable as a veterinary pharmaceutical manufacturer with overlapping therapeutic areas (dermatology, endocrinology, pain management), though Zoetis operates at vastly greater scale.
• Elanco Animal Health: Global animal health company with companion animal and livestock portfolios spanning therapeutics, vaccines, and parasiticides. Comparable as a broad-line veterinary pharma peer, particularly in dermatology and endocrinology, though Elanco is publicly traded and significantly larger than Dechra's US entity.
• Dechra Pharmaceuticals PLC: The publicly-listed UK parent company of Dechra Veterinary Products LLC, operating the global group portfolio. Included as the most directly comparable parent entity that owns the same product IP, runs the same specialty-pharma strategy, and competes in identical veterinary channels across Europe and other regions.

Direct peers

• Norbrook Laboratories: Privately held Northern Ireland-based veterinary pharmaceutical manufacturer offering generic and branded companion-animal and livestock products globally. Comparable as an independent specialty veterinary pharma peer, with overlapping focus on anti-infectives and NSAIDs.
• Ceva Santé Animale: Privately held French multinational veterinary pharmaceutical company with strong positions in companion animal pharmaceuticals, vaccines, and reproduction. Comparable as a specialty animal health peer of similar size and strategic focus on innovation in niche therapeutic areas.
• Virbac: Independent global animal health company specializing in companion animal pharmaceuticals, vaccines, and nutrition. Closely comparable to Dechra given its specialty pharmaceutical focus, similar portfolio breadth in dermatology and parasiticides, and veterinary-exclusive go-to-market approach.
• Vetoquinol: Independent French veterinary pharmaceutical company focused on companion animals and livestock, with strong emphasis on osteoarthritis pain management, dermatology, and internal medicine. A direct comparable peer given similar specialty pharmaceutical positioning, mid-sized scale, and veterinary-exclusive channel strategy.
• Phibro Animal Health: Diversified animal health and mineral nutrition company with pharmaceutical and vaccine portfolios for companion animals and livestock. Comparable as a specialty veterinary pharmaceutical peer, though with a heavier livestock tilt than Dechra's companion-animal focus.

Emerging players

• Heska (Antech Imaging): Specialty veterinary diagnostics and pharmaceutical company (now part of Mars Petcare/Antech) focused on point-of-care diagnostics and select therapeutics. Comparable as a smaller specialty player in the veterinary channel with overlapping customer base, though Heska's primary focus is diagnostics rather than pharmaceuticals.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/DechraUS
• LinkedInlinkedin.com/company/dechra-veterinary-products
• Instagraminstagram.com/dechraus

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dechra Veterinary Products